EORTC Melanoma Group achievements
| العنوان: | EORTC Melanoma Group achievements |
|---|---|
| المؤلفون: | Ulrich Keilholz, Alexander C.J. van Akkooi, Martin C. Mihm, Gaetan de Schaetzen, Serge Leyvraz, Alan Spatz, Dirk Schadendorf, Léon C van Kempen, Caroline Robert, Alessandro Testori, Esther de Vries, Martin G. Cook, Julia Newton-Bishop, Ghanem Elias Ghanem, Poulam M. Patel, R. Karra Gurunath, Alexander M.M. Eggermont, Stefan Suciu |
| المساهمون: | Surgery, Public Health |
| المصدر: | Ejc supplements, 10(1), 112-119 European journal of cancer, 10 (1 European Journal of Cancer Supplements, 10(1), 112-119. Elsevier Ltd. |
| بيانات النشر: | European Organisation for Research and Treatment of Cancer. Published by Elsevier Ltd. |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Prognostic factors, Targeted therapy, Clinical research, Pegylated interferon, Internal medicine, medicine, Temozolomide, neoplasms, Melanoma, business.industry, Cancer, Sentinel node, medicine.disease, Surgery, Cancérologie, Interferon, Lymphadenectomy, business, medicine.drug |
| الوصف: | Since its inception in 1969, the EORTC Melanoma Group has employed a multidisciplinary approach in the fight against melanoma and has registered significant achievements in many areas of melanoma treatment and research. The group showed that sentinel node (SN) tumor burden according to the Rotterdam Criteria and the microanatomic location were the most important prognostic factors for melanoma-specific survival and non-SN positivity in the completion lymph node dissection specimen. They demonstrated that extended schedule escalated dose temozolomide is feasible and has an acceptable safety profile. They also showed that the interferon-a targeted therapy should occur in a targeted patient population, and should probably not be offered to 70% of the patients that are currently being given this treatment. Through EORTC trial 18991, Sylatron™, pegylated interferon a-2b, for the treatment of melanoma patients with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, was approved by the US FDA. The present article describes the achievements and future strategies of the Melanoma Group. © 2012 European Organisation for Research and Treatment of Cancer. SCOPUS: ar.j info:eu-repo/semantics/published |
| وصف الملف: | application/pdf; 1 full-text file(s): application/pdf |
| اللغة: | English |
| تدمد: | 1359-6349 |
| DOI: | 10.1016/S1359-6349(12)70020-4 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c57594de9bc5f75636983568fdf30aTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b7c57594de9bc5f75636983568fdf30a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13596349 |
|---|---|
| DOI: | 10.1016/S1359-6349(12)70020-4 |